EUVIMEDEUVIMED entdecken
Crossref

L26/P-416 Fifteen-Year Outcomes of Fertility Preservation in Women with Breast Cancer in a tertiary care centre

M.S. ElFarran, A. Sood, M. Lokman, D. Gould, K. Palinska-Rudzka

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.750 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M.S. ElFarran und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What is the long-term efficacy of the fertility preservation (FP) service provided to women with breast cancer? Summary answer Among 320 women undergoing FP, 3.4% deceased. 9% returned to use cryopreserved material. Clinical pregnancy and live birth were 3.9% and 3.5% per patient, respectively. What is known already Counselling and offering FP is standard of care for women of reproductive age undergoing planned gonadotoxic treatments, such as chemotherapy for malignancy (Rives et al., 2022). Compared with non-oncological FP patients, return-to-use rates among oncology patients are consistently low (Porcu et al., 2022). Study design, size, duration This was a retrospective cohort study including women of reproductive age with breast cancer who underwent FP over a 15-year period (2009–2024). Participants/materials, setting, methods A total of 320 patients referred for FP at a tertiary fertility centre within a university hospital in Northwest England were included. Baseline demographic and treatment data were collected prospectively at the time of presentation to the service, while pregnancy and live birth outcomes were assessed retrospectively using electronic medical records.Primary outcomes included median numbers of cryopreserved oocytes or embryos, return-to-use rates, and clinical pregnancy and live birth rates per patient. Main results and the role of chance Data from 320 patients undergoing 338 FP cycles were analysed; this included patients who underwent dual stimulation to maximise the number of cryopreserved oocytes or embryos. Mean age at presentation was 29 years (range 22–43). Reported ethnicity was White British (47.5%), Asian (3.4%), African (2.8%), White European (2.5%), with the remainder not stated.Oocyte cryopreservation was undertaken by 216/320 (67.5%) patients, while 104/320 (32.5%) opted for embryo cryopreservation. Eighteen patients underwent dual stimulation. Twelve of 338 cycles (3.4%) were cancelled due to COVID-19 disruption, medical contraindications, or poor ovarian response.The median number of cryopreserved oocytes was 11 (IQR 7–17), and the median number of stored embryos was 4 (IQR 2–7).During follow-up, 11/320 (3.4%) patients died. Of the remaining 309 patients, 28 (9.0%) returned to use their stored gametes or embryos. Among these, 11 patients achieved a clinical pregnancy (3.9% per patient) and 10 achieved a live birth (3.5% per patient). One patient experienced a miscarriage followed by a live birth in a subsequent frozen embryo transfer cycle, and one patient achieved two live births. Limitations, reasons for caution Limitations include the retrospective design and incomplete follow-up for some cycles outsourced to satellite centres during the COVID-19 pandemic. Additionally, some patients with adequate ovarian reserve underwent fresh assisted reproduction cycles before electing to use stored material, which may have underestimated utilisation rates. Wider implications of the findings Fertility preservation is integral to oncological care, yet long-term real-world outcomes remain limited. This large 15-year cohort demonstrates low return-to-use rates but meaningful reproductive success among returners. The findings inform realistic counselling, service planning, resource allocation, and underscore the need for evidence-based guidance on cryostorage duration and cost-effectiveness in oncology. Trial registration number No

Zitieren

APA

ElFarran, M., Sood, A., Lokman, M., Gould, D., & Palinska-Rudzka, K. (2026). L26/P-416 Fifteen-Year Outcomes of Fertility Preservation in Women with Breast Cancer in a tertiary care centre. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.750

Vancouver

ElFarran M, Sood A, Lokman M, Gould D, Palinska-Rudzka K. L26/P-416 Fifteen-Year Outcomes of Fertility Preservation in Women with Breast Cancer in a tertiary care centre. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.750

BibTeX
@article{ElFarran2026,
  author = {ElFarran, M.S. and Sood, A. and Lokman, M. and Gould, D. and Palinska-Rudzka, K.},
  title = {L26/P-416 Fifteen-Year Outcomes of Fertility Preservation in Women with Breast Cancer in a tertiary care centre},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.750}
}
Kostenlos starten →